Financial Data and Key Metrics Changes - Organic revenue growth was reported at 6.1%, with a balance between price (3.3%) and volume/mix (2.8%) [6][10] - Organic profit growth for the quarter was 7.4%, leading to a year-to-date organic profit growth of 9.7% [7][32] - Reported revenue declined by 0.6% due to net M&A headwinds and foreign exchange impacts [12][11] Business Line Data and Key Metrics Changes - Oral Health revenues grew by 8.2% in the quarter, driven by strong performance from Sensodyne and parodontax [15] - VMS (Vitamins, Minerals, and Supplements) grew by 3.7%, with Centrum facing tough comparatives from the previous year [16] - Pain Relief returned to growth at 3.1%, while Respiratory Health saw a 9.1% increase [17][18] Market Data and Key Metrics Changes - North America experienced organic revenue growth of 4.8%, with significant contributions from Oral Health and Pain Relief [19] - Europe, Middle East, Africa, and Latin America saw organic revenue growth of 6.1%, driven by pricing strategies [21] - Asia Pacific reported an 8.2% increase in organic revenue, with double-digit growth in China [25][28] Company Strategy and Development Direction - The company is focused on optimizing its portfolio through active brand management and has increased its stake in the China joint venture [8][30] - Capital allocation priorities include investing in brand growth, completing share buybacks, and pursuing strategic M&A opportunities [33][41] - The company aims to achieve organic revenue growth of 4% to 6% and high-single-digit organic profit growth for the full year [36][40] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in meeting full-year guidance despite foreign exchange headwinds and uncertainties in cold and flu season performance [9][37] - The company is prepared for the cold and flu season with healthy sell-in and expects continued market share gains [54][80] - Management highlighted the importance of maintaining a balance between price and volume growth moving forward [13][88] Other Important Information - The company raised approximately £900 million in bonds to refinance maturing debt, indicating strong demand for its financial instruments [9] - The company has returned over £1 billion to shareholders through dividends and share buybacks this year [41] Q&A Session Summary Question: Outlook for 2024 and key sources of uncertainty - Management is confident in achieving FY 2024 guidance, with cold and flu season and foreign exchange being noted as uncertainties [48][50] Question: VMS business slowdown - The deceleration in VMS is attributed to tough comparatives for Centrum, with expectations for a sequential pickup in Q4 [49][56] Question: FX leverage effects - FX impacts were noted as an outlier in Q3, with expectations for smaller effects in Q4 [58][59] Question: China OTC business visibility - The company has been operationally running the China OTC business and is focused on integrating field forces post-acquisition [62] Question: Performance of Panadol - Panadol is maintaining market share despite a normalization of demand following a tripledemic last year [65][68] Question: Eroxon launch and retailer uptake - Eroxon has seen good retailer uptake, with distribution above 80% among major customers, and advertising efforts are underway [70][72]

Core Insights - Haleon PLC Sponsored ADR (HLN) has a stronger Zacks Rank of 2 (Buy) compared to Insulet (PODD) which has a Zacks Rank of 3 (Hold) indicating a more favorable earnings outlook for HLN [3] - Value investors utilize various traditional metrics to identify undervalued companies, including P/E ratio, P/S ratio, earnings yield, and cash flow per share [4] Valuation Metrics - HLN has a forward P/E ratio of 22.43, significantly lower than PODD's forward P/E of 76.64, suggesting that HLN may be undervalued relative to its earnings potential [5] - The PEG ratio for HLN is 3.08, while PODD's PEG ratio is 4.35, indicating that HLN's expected earnings growth is more favorable when adjusted for its price [5] - HLN's P/B ratio stands at 2.28, compared to PODD's P/B of 16.32, further highlighting HLN's relative valuation advantage [6] - Based on these valuation metrics, HLN holds a Value grade of B, while PODD has a Value grade of D, suggesting that HLN is the more attractive option for value investors [6]

Core Insights - PubMatic has launched a new collaborative approach to supply path optimization (SPO) for Haleon, aiming to enhance efficiency and sustainability in digital advertising [1][2] - Haleon has selected PubMatic as a preferred supply partner to streamline access to video, display, and connected TV (CTV) inventory globally [2][3] - The partnership focuses on maximizing commercial efficiency, transparency, and data-driven insights while reducing carbon emissions related to Haleon's media investments [3][4] Company Overview - PubMatic is an independent technology company that delivers digital advertising's supply chain of the future, empowering digital content creators to control access to their inventory and increase monetization [5] - Haleon is a global leader in consumer health, with a diverse product portfolio that includes categories such as Oral Health, Pain Relief, and Vitamins, Minerals, and Supplements (VMS) [6]

Core Insights - Eroxon® is the first and only FDA cleared over-the-counter gel for erectile dysfunction (ED) available without a prescription, now available for pre-order and set to launch in October 2024 [1][7] - Clinical studies demonstrate that Eroxon® is safe and effective, providing results within 10 minutes, addressing a significant unmet need compared to existing prescription solutions that may take up to an hour [2][3] Product Details - Eroxon® stimulates nerve endings in the penis to help men achieve and maintain an erection, enhancing intimacy and connection in relationships [3][4] - The application process involves massaging the gel onto the head of the penis, which can be done by the user or their partner as part of foreplay [4] Market Context - Erectile dysfunction affects approximately 30 million men in the U.S., with prevalence increasing with age; half of men over 40 experience ED [6] - Haleon aims to make Eroxon® accessible to millions of men affected by ED, emphasizing the importance of sexual health as part of overall wellness [4][8]

HALEON 2024 Half year results August 2024 Disclaimer This presentation contains certain statements that are, or may be deemed to be, "forward-looking statements" (including for purposes of the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934). Forward-looking statements give Haleon's current expectations and projections about future events, including strategic initiatives and future financial c ...

Haleon plc (NYSE:HLN) Q2 2024 Earnings Call August 1, 2024 4:00 AM ET Company Participants Sonya Ghobrial - Investor Relations Brian McNamara - Chief Executive Officer Tobias Hestler - Chief Financial Officer Conference Call Participants Guillaume Delmas - UBS Bruno Monteyne - Bernstein Chris Pitcher - Redburn Atlantic David Hayes - Jefferies Rashad Kawan - Morgan Stanley Jeremy Fialko - HSBC Olivier Nicolai - Goldman Sachs Celine Pannuti - JPMorgan Iain Simpson - Barclays Operator Good morning, all. Thank ...

Core Insights - Haleon PLC Sponsored ADR (HLN) is currently rated as a 2 (Buy) by Zacks, indicating a positive earnings outlook, while LeMaitre Vascular (LMAT) holds a 3 (Hold) rating, suggesting a less favorable position for value investors [2][5]. Valuation Metrics - HLN has a Price-to-Book (P/B) ratio of 1.94, significantly lower than LMAT's P/B ratio of 6.33, indicating that HLN may be undervalued compared to LMAT [4]. - The forward Price-to-Earnings (P/E) ratio for HLN is 18.78, while LMAT's forward P/E ratio is considerably higher at 49.05, further suggesting that HLN presents a more attractive valuation [8]. - HLN's PEG ratio stands at 2.50, compared to LMAT's PEG ratio of 2.65, indicating that HLN's expected earnings growth is more favorable relative to its price [8]. Value Grades - Based on various valuation metrics, HLN has received a Value grade of B, while LMAT has been assigned a Value grade of D, highlighting HLN's superior position for value investors [9].

Core Viewpoint - Acadia Pharmaceuticals is focused on developing innovative treatments for central nervous system disorders and rare diseases, with a commercial portfolio that includes Nuplazid and Daybue, and is actively expanding its pipeline to reduce dependency on Nuplazid sales [1][6]. Financial Performance - In Q1 2024, Nuplazid sales rose by 10% year over year to $129.9 million, attributed to increased new patient starts and higher pricing benefits [2]. - Daybue, launched in April 2023, generated net product sales of $75.9 million in its third full quarter, contributing to incremental revenues for the company [8][17]. Product Development and Pipeline - Acadia has expanded its licensing agreement with Neuren, acquiring rights to market trofinetide outside North America and exclusive global rights to NNZ-2591 for Rett syndrome and Fragile X syndrome [3]. - The company initiated a phase III COMPASS study for carbetocin nasal spray (ACP-101) targeting hyperphagia in Prader-Willi syndrome, with plans to submit a new drug application if successful [5][20]. - Acadia is also developing ACP-204 for Alzheimer's disease psychosis, having started a mid-stage study to evaluate its safety and efficacy [11]. Legal and Competitive Landscape - In late 2023, favorable court rulings in Delaware reinforced Acadia's patent for Nuplazid, which is expected to preserve its sales growth potential due to the lack of generic alternatives [4][19]. - Acadia faces competition from other companies, such as Axsome Therapeutics, which has a portfolio of CNS product candidates and has received FDA approval for its product Auvelity [22]. Market Position and Stock Performance - Acadia's stock has seen a decline of 42.4% year to date, contrasting with a 2.7% decline in the industry [18]. - The company currently holds a Zacks Rank 2 (Buy), indicating a favorable outlook compared to other stocks in the drug/biotech industry [13][23].

Continued good momentum despite China declining low-single digit due to a tough comparative Volume /mix Pain Relief – Double digit decline mainly due to challenging Fenbid comparative in China in Q1 2023 when revenue more than doubled Strong Q1 organic profit growth 23.1% 24.2% +220bps (30)bps (80)bps 12 1. Reconciliation of IFRS to Adjusted results can be found in the Appendix 2. Net M&A: disposal of Lamisil and includes the impact of Manufacturing Service Agreements (MSAs) 3. Refers to Organic. Definition ...

As usual, we will take you through some prepared remarks before opening the call to Q&A. For those listening to our webcast, whoÂ'd like to ask a question, please use the dial-in details on Page 3 of todayÂ's release. Also, while the focus today is on revenue performance, weÂ've also provided group profit and margin detail on both a reported and an adjusted basis, with a full reconciliation, including one for organic revenue growth in the appendix. As a reminder and for information, we do not intend to prov ...